Novartis India schedules its 77th AGM for July 31, 2025, and notifies shareholders via email about tax deduction on dividends.
Novartis India Announces 77th AGM and Dividend TDS Communication to Shareholders
Mumbai, 2nd July, 2025
Novartis India Ltd (BSE: 500672), one of India’s top pharmaceutical companies, has formally intimated the convening of its 77th Annual General Meeting (AGM), to be held on Thursday, July 31, 2025. The intimation made under Regulation 30 of the SEBI (LODR) Regulations, 2015, was released through newspaper and also to the Bombay Stock Exchange (BSE) to make all members and stakeholders aware of this.
As a part of its transparent communication process, the company has also issued an email communication to shareholders on Tax Deduction at Source (TDS) on dividend income, subject to payment of dividend in case the dividend is approved at the next AGM. This is as per statutory requirement under the Income Tax Act, 1961.
Key Highlights:
- 77th AGM Date: July 31, 2025
- Mode of Communication: Newspaper publication and email to shareholders
- Purpose: Informing shareholders of AGM and TDS guidelines on dividends
- BSE Code: 500672
- Company Website: Novartis India Ltd on BSE
AGM Details and Agenda
More Read
The 77th AGM will be a critical juncture for Novartis India, offering shareholders an opportunity to discuss the company’s performance over the past fiscal year, review audited financials, and vote on proposed dividends. The meeting is expected to cover:
- Presentation of the Annual Report for FY 2024–25
- Adoption of financial statements
- Declaration of final dividend
- Appointment or reappointment of directors
- Auditor’s remuneration
- Other resolutions and general business matters
The AGM will be conducted in compliance with all relevant corporate governance standards and regulatory guidelines. Details about the AGM proceedings, participation guidelines, and e-voting instructions are expected to be shared separately through the company’s official communication channels.
Tax Deduction at Source (TDS) Communication
In line with Indian tax laws, Novartis India has proactively informed shareholders via email regarding TDS on dividends. If the proposed dividend is approved at the AGM, shareholders will receive dividend payouts after deducting applicable taxes.
Important notes from the company’s communication:
- Shareholders are requested to ensure that their PAN details are updated with their Depository Participant or Registrar and Transfer Agent to avoid higher TDS.
- For shareholders eligible for a lower or nil TDS rate (such as those under specific tax treaties or exempt categories), valid documentation must be submitted by the prescribed deadline.
- TDS certificates will be issued in due course after the dividend payout.
This approach by Novartis reflects its commitment to regulatory compliance and investor awareness, ensuring all shareholders are well-informed about their tax liabilities and options.
About Novartis India Ltd
Novartis India Ltd is a leading pharmaceutical firm, involved in the distribution and marketing of branded generic drugs and healthcare solutions. Novartis is recognized for its ethical practices, scientific excellence, and patient-centric philosophy in its business practices throughout India.
It is a subsidiary of the global Novartis Group, which is present in more than 150 countries and is known for its position of leadership in prescription pharmaceuticals, eye care, and generics.
Investor Guidance and Resources
Shareholders and market participants are encouraged to:
- Review the AGM notice and annual report once published
- Ensure their contact and PAN details are up to date
- Submit relevant tax exemption forms well in advance
- Track updates through official channels and the BSE India website
As a listed company, Novartis India continues to uphold best practices in corporate governance, investor relations, and statutory disclosures.
Conclusion
With its forthcoming 77th Annual General Meeting and transparency being offered on TDS regulations, Novartis India Ltd has yet again shown its eagerness to undertake transparent corporate communication. Shareholders are suggested to remain updated and take an active part in the AGM proceedings of FY 2024–25.
